Expression of miR-92a and miR-125b and Their Association with Chemoradiotherapy Response in Locally Advanced Cervical Cancer
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041723 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Renny Anggia Julianti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, C…. Hauptthemen laut MEDLINE: MicroRNAs, Uterine Cervical Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cervical cancer remains a major cause of morbidity and mortality, with most cases in Indonesia diagnosed at a locally advanced stage. Although concurrent chemoradiotherapy is the standard treatment, response varies. Dysregulation of microRNAs (miRNAs), particularly oncogenic miR-92a and tumor suppressor miR-125b, may contribute to treatment resistance. This study aimed to evaluate the association between miR-92a and miR-125b expression and chemoradiotherapy response in locally advanced cervical cancer. This single-center retrospective cohort study included patients with stage IB3–IVA cervical cancer treated with chemoradiotherapy between 2019 and 2025. miRNA expression levels were measured from pretreatment tumor biopsy specimens. Poor response was defined as incomplete response or disease progression after treatment. Appropriate comparative, predictive, and survival analyses were performed. Sixty-eight patients were included. Poor response was significantly associated with underweight body mass index, elevated miR-92a, and reduced miR-125b expression (p < 0.05). High miR-92a and low miR-125b expression were also associated with shorter overall survival (p < 0.001). A combined model incorporating BMI, miR-92a, and miR-125b showed good predictive performance. Elevated miR-92a and reduced miR-125b are associated with poor treatment response and worse survival. These miRNAs may support risk stratification and treatment personalization in locally advanced cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Central Jakarta 10430, Indonesia.
- Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Central Jakarta 10310, Indonesia.
ORCID-Profile: Renny Anggia Julianti, Andi Darma Putra, Ahmad Fuady, Gatot Purwoto
Zitieren
APA
Julianti, R. A., Putra, A. D., Fuady, A., Nuranna, L., Purwoto, G., Nuryanto, K. H., & Yudhistira, M. Y. (2026). Expression of miR-92a and miR-125b and Their Association with Chemoradiotherapy Response in Locally Advanced Cervical Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041723
Vancouver
Julianti RA, Putra AD, Fuady A, Nuranna L, Purwoto G, Nuryanto KH, et al. Expression of miR-92a and miR-125b and Their Association with Chemoradiotherapy Response in Locally Advanced Cervical Cancer. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041723
BibTeX
@article{Julianti2026,
author = {Julianti, Renny Anggia and Putra, Andi Darma and Fuady, Ahmad and Nuranna, Laila and Purwoto, Gatot and Nuryanto, Kartiwa Hadi and Yudhistira, Muhammad Yurizar},
title = {Expression of miR-92a and miR-125b and Their Association with Chemoradiotherapy Response in Locally Advanced Cervical Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041723}
}
EUVIMED